Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05705531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary endpoints: 7 to 1v23Show 5 more changesShow less
Enrollment target: 230 to 190
Interventions: Biospecimen Collection (Procedure), Electronic Health Record Review (Other), Magnetic Resonance Imaging (Procedure), Survey Administration… to Archive Sample Retrieval (Procedure), Biospecimen Collection (Procedure), Electronic Health Record Review (Other), Magnetic Resonance…
Eligibility criteria expanded, about 128 words
Study description expanded, about 56 words
Site details revised at 2 of 29 sites
Show 21 earlier versionsHide 21 earlier versions
MinorSite contacts updated at 1 of 29 sitesv22
MinorStudy sites: 28 to 29v21
MinorStudy sites: 26 to 28v20
MinorStudy sites: 23 to 26
Study description revised
v19
MinorStudy sites: 21 to 23v18
MinorStudy sites: 20 to 21v17
MinorStudy sites: 19 to 20
Collaborators shortened, about 4 words
v16
MinorStudy sites: 18 to 19v15
MinorStudy sites: 16 to 18v14
MinorRe-verified, no change to tracked fieldsv13
MinorStudy sites: 12 to 16v12
NotableStart date: May 22, 2023 to Aug 18, 2023v11
MinorStudy sites: 10 to 12v10
MinorStudy sites: 8 to 10v9
MinorStudy sites: 7 to 8v8
MinorStudy sites: 5 to 7v7
MinorStudy sites: 3 to 5v6
MinorRe-verified, no change to tracked fieldsv5
MinorStudy sites: 2 to 3v4
NotableTrial status: Not Yet Recruiting to Recruitingv3Show 4 more changesShow less
Enrollment target: 161 to 230
Study sites: 0 to 2
Start date changed from estimate of May 20, 2023 to May 22, 2023
Collaborators expanded, about 4 words
NotablePrimary and study completion dates: Sep 30, 2027 to Oct 1, 2028v2Show 8 more changesShow less
Primary endpoints: 1 to 7
Start date: Aug 14, 2023 to May 20, 2023
Interventions: Clinical Evaluations (Procedure), Patient Self Reporting (Other), Study Blood Sampling (Procedure) to Biospecimen Collection (Procedure), Electronic Health Record Review (Other), Magnetic Resonance Imaging (Procedure), Survey Administration…
Eligibility criteria expanded, about 30 words
Secondary endpoints revised (2)
Study description shortened, about 28 words
Collaborators shortened, about 4 words
Study title expanded, about 3 words
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.